Velinotamig (BCMAxCD3 T cell engager): treatment-refractory autoimmune diseases driven by long-lived plasma cells (GlobeNewswire) - Aug 6, 2026 - "Additional multi-dose regimen data from the study are expected to be shared in Q4 2026....Cullinan plans to initiate a global Phase 1/2 basket study in early 2027 in patients with autoimmune cytopenias, including immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA)."
New P1/2 trial • P1 data • Autoimmune Hemolytic Anemia • Immune Thrombocytopenic Purpura • Systemic Lupus Erythematosus
|